The social brain: Understanding autism

  • Autism Research
Speaker Nancy Kanwisher, Ph.D.
Massachusetts Institute of Technology
Date & Time


Location

Gerald D. Fischbach Auditorium
160 5th Avenue
New York, NY 10010 United States

Autism Research

Autism Research lectures bring together scientists and scholars to discuss diverse and important topics related to autism.

Video Thumbnail

By clicking to watch this video, you agree to our privacy policy.

 
On 23 September, Nancy Kanwisher discussed the functional architecture of the social brain as an avenue for considering which functions are affected and which are preserved in autism.

Her talk was part of the Simons Foundation Autism Research lecture series.
 

About the Lecture

Humans are a highly social species, allocating numerous brain regions to distinct aspects of social cognition. These regions and corresponding mental abilities serve as tools for understanding which functions are lost and which are preserved in autism.

Autism is characterized by a highly uneven cognitive profile in which some mental functions are preserved or enhanced, and others are disrupted. An important asset in the search to understand this complex disorder comes from the study of the typical human mind and brain.

In this talk, Nancy Kanwisher considered the functional architecture of the social brain as an avenue for considering which functions are affected and which are preserved in autism.

About the Speaker

Nancy Kanwisher is professor of cognitive neuroscience at the Massachusetts Institute of Technology (MIT) and an investigator at MIT’s McGovern Institute for Brain Research. After receiving her B.S. and Ph.D. from MIT, Kanwisher served on the faculty at the University of California, Los Angeles and Harvard University before returning to MIT in 1997. Kanwisher has received the Troland Research Award, MacVicar Faculty Fellow teaching award and Golden Brain Award. She is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.

Past Lectures

How emotions shape our memories

Kelsey C. Martin, M.D., Ph.D.Executive Vice President, Autism and Neuroscience
Leonard Mlodinow, Ph.D.Physicist and Author

Have you ever contemplated the difference between a feeling, a thought and a memory? And how do all these things fit together in making us who we are?

Leonard Mlodinow is a theoretical physicist and best-selling author. In his latest book, “Emotional: How Feelings Shape Our Thinking,” he unpacks the role emotions play in our thinking and mental well-being.

Kelsey Martin, director of the Simons Foundation Autism Research Initiative (SFARI) and the foundation’s neuroscience collaborations, has spent much of her career as a neuroscientist seeking to understand better how experiences change brain connectivity to store long-term memories.

What do we mean by ‘autism risk genes’?

David Ledbetter, Ph.D.
Chief Clinical Officer, Dascena

Joseph Buxbaum, Ph.D.
Director, Seaver Autism Center
Professor, Psychiatry, Neuroscience, Genetics and Genomic Sciences
Vice Chair for Research and Vice Chair for Mentoring, Psychiatry, Icahn School of Medicine at Mount Sinai

Heather Mefford, M.D., Ph.D.
Full Member, St. Jude Children’s Research Hospital

David Ledbetter and Joseph Buxbaum discussed whether there are genes for which mutations confer risk specific to autism or whether these genes are really conferring general risk of disrupted brain development. The discussion was moderated by Heather Mefford.

Small molecules, genes and antisense oligonucleotides: Industry perspectives on treatment development for ASD

Federico Bolognani, M.D., Ph.D.
Vice President, Head of Clinical Science, Axial Therapeutics

Stuart Cobb, Ph.D.
Chief Scientific Officer, Neurogene; Research Fellow, University of Edinburgh

Yael Weiss, M.D., Ph.D.
Vice President, Business Development, Ultragenyx

Randy Carpenter, M.D.
Chief Medical Officer, Rett Syndrome Research Trust; Co-Founder, Allos Pharma

Federico Bolognani, Stuart Cobb, and Yael Weiss joined a panel to discuss new industry developments on the use of small molecules, gene therapy and antisense oligonucleotides as treatment approaches for autism spectrum disorders (ASD). The panel discussion was moderated by Randall Carpenter.

Subscribe to our newsletter and receive SFARI funding announcements and news